Big Cypress Acquisition announced that, starting Feb 9, holders of the units sold in the SPAC’s IPO of 11.5 million units may elect to separately trade the shares of common stock and redeemable warrants.
Those units not separated will continue to trade on the Nasdaq under BCYPU, and the shares of common stock and redeemable warrants that are separated will trade under BCYP and BCYPW, respectively.
The SPAC plans to target a business in the life sciences industry.
Big Cypress is led by CEO Samuel Reich, who co-founded Biscayne Neurotherapeutics in 2011 and served as its executive chairman until the company was sold Supernus Pharmaceuticals in 2018. Read more.
